fastFISH auto-amniocyte launched in the U.S.
Ikonisys’ fastFISH® auto-amniocyte application was cleared for marketing in the U.S. This product allows for the automated identification and enumeration of chromosomes 13, 18, 21, X, and Y in amniotic fluid cells via fluorescence in situ hybridization, or FISH.

Numerical aberrations of these chromosomes are linked to birth defects, such as down syndrome. The fastFISH auto-amniocyte product is designed to run on the Ikoniscope® robotic digital microscopy platform.

“We believe that physicians and consumers will appreciate fastFISH® auto-amniocyte’s rapid and reliable functionality,” says Petros Tsipouras, M.D., chairman and CEO.

“Further, this application provides laboratories with an economical solution to the industry-wide shortage of trained technical personnel,” he adds.

Previous articleFDA Approves Vectibix to Treat Patients with Metastatic Colorectal Cancer
Next articleNHGRI Funds Assessment of Public Attitudes of Population-Based Studies on Genes and Environment